This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Abstract Cardio-oncology is a rapidly growing field of cardiovascular (CV) medicine that has resulted from the continuously increasing clinical demand for specialized CV evaluation, prevention and management of patients suffering or surviving from malignant diseases.
and sleep apnea prevalence in cardio-oncology patients was the same or greater than other traditional risk factors. Sleep apnea prevalence in cardiology patients was similar to the rates in patients with heart failure.,
The review underscores the critical need to consider environmental factors, especially air pollution, in cardio-oncology risk assessment and patient management,” said Xiaoquan Rao , MD, PhD, senior author of the study and a cardiologist at Tongji Hospital at the Tongji Medical College in Wuhan, China.
An expert panel report published in JACC: CardioOncology provides practical recommendations during cancer therapy supported by high-quality evidence that can be applied across diverse settings, and highlights the significant gaps in knowledge in cardio-oncology.
Artificial intelligence is poised to transform cardio-oncology by enabling personalized care for patients with cancer, who are at a heightened risk of cardiovascular disease due to both the disease and its treatments. Circulation: Genomic and Precision Medicine, Ahead of Print.
The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors. Circulation, Ahead of Print.
However, experts in cardio-oncology from the European Society of Cardiology (ESC) emphasize that heart and cardiovascular health must be included as early as possible in the patient's cancer treatment plan to ensure the best possible outcomes.
The role of wearable technology in detecting AF in cardio-oncology has not been well defined. Patients with CLL are at increased risk of developing atrial fibrillation (AF), however AF is a known side effect of ibrutinib therapy as well and is associated with worse outcomes.
As the field of cardio-oncology continues to expand rapidly, guidance on the management of such toxicities and the development of imaging technologies is crucial. These methods have unique considerations and in recent years have made significant progress in their diagnostic capabilities in this patient population.
Cangrelor, a potent intravenous P2Y12 platelet inhibitor, has demonstrated effectiveness in reducing ischemic events without a corresponding increase in severe bleeding during percutaneous coronary intervention, as evidenced by the CHAMPION-PHOENIX trial.
After two full days covering a wide range of issues and experts, the final day will include a joint session with the American College of Cardiology ( ACC ) and the American Society of Clinical Oncology ( ASCO ). Cardio-Oncology Educational Training: What Do I Need to Learn? How to Structure?:
The emerging field of cardio-oncology is paving the way for expert, multidisciplinary heart care before, during and after cancer treatment to mitigate adverse effects on cardiovascular health.
The Heart Failure Society of America has released a scientific statement outlining its insights on the link between heart failure and cancer, the two leading causes of mortality and morbidity in the U.S. The statement was published Oct. 15 in the Journal of Cardiac Failure.
Finally, it discusses the existing gaps between preclinical models and clinical observations in patients, how these discrepancies affect regulatory pathways and the drug development process in cardio-oncology and provides recommendations for closing these gaps.
The annual Global Cardio-Oncology Summit was held in September, bringing together healthcare professionals in the context of cardiovascular disease and cancer.
The baseline risk of CTRCD was graded according to the risk score proposed by the Heart Failure Association (HFA) Cardio-Oncology Working Group and the International Cardio-Oncology Society (ICOS). CTRCD and its severity were defined according to the current European Society of Cardiology (ESC) guidelines.
The announcement specifically highlighted Philips’ first-of-their-kind… Segmented Wall Motion app – an automated tool for segmental wall motion scoring and identifying disorders such as coronary artery disease and cardio-oncology issues.
There is need for development of a stronger evidence base to guide clinical practice in cardio-oncology. The establishment of multicentre international registries and national-level healthcare data linkage projects are important steps towards facilitating enrichment of cardio-oncology research programmes.
The new FDA-cleared AI-enabled applications include the industry’s first automated tool for segmental wall motion scoring of the heart to quickly and objectively identify disorders including coronary artery disease and cardio-oncology issues in seconds.
Further collaborative studies in cardio-oncology with real-world data are warranted to improve the rate of baseline cardiovascular risk assessment in patients with cancer scheduled for cardiotoxic cancer treatment. Baseline cardiac evaluation in the combined AC/TZ cases was 27.2% preoperative, 66.0% pre-AC and 86.6%
Cardio-oncology is a new field of interest in cardiology focusing on the detection and treatment of cardiovascular diseases, such as arrhythmias, myocarditis, and heart failure, as side-effects of chemotherapy and radiotherapy. The association between chemotherapeutic agents and arrhythmias has previously been established.
As we step into 2024, the field of cardiology continues to offer exciting opportunities for knowledge exchange and networking at in-person conferences. Here is a preview of the upcoming cardiology conferences planned for 2024.
Chadi Alraies discusses highlights from the American Heart Association (AHA) Scientific Sessions 2023, which were held in Philadelphia, Pennsylvania (PA), on November 11-13, 2023. There were many important developments in presented in key clinical trial presentations and publications stemming from the AHA Scientific Sessions 2023.
The American College of Cardiology (ACC) held its 73 rd annual scientific session and expo April 6-8, 2024 in Atlanta, Georgia. Here is our curated list of the top sessions. EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content